WO2004066998A1 - 安定な経口用固形医薬組成物 - Google Patents
安定な経口用固形医薬組成物 Download PDFInfo
- Publication number
- WO2004066998A1 WO2004066998A1 PCT/JP2004/000896 JP2004000896W WO2004066998A1 WO 2004066998 A1 WO2004066998 A1 WO 2004066998A1 JP 2004000896 W JP2004000896 W JP 2004000896W WO 2004066998 A1 WO2004066998 A1 WO 2004066998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- ramosetron
- group
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Definitions
- the present invention relates to a stable oral solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which comprises a specific compound having a carbonyl group.
- the present invention also relates to a method for stabilizing an oral solid pharmaceutical composition of ramoseton or a pharmaceutically acceptable salt thereof, which comprises mixing a specific compound having a hydroxyl group. Things.
- the present invention also relates to a novel method for treating irritable bowel syndrome with diarrhea. Background art
- Ramosetron has the chemical name of (1-)-1- (R) -5-[(1-methyl-1H-indole-3-yl) potassium) -1,4,5,6,7-tetrahydro-1H- Benzymidazole ((1-)-1- (R) -5-[(1-methyl-1H-indole-3-1-l) carbonyl] -1,4,5,6, ⁇ ⁇ ⁇ -tetrahydro-1H-benzimidazole).
- a series of tetrahydrobenzimidazole derivatives containing the ramosetron and pharmaceutically acceptable salts thereof have excellent serotonin (5-HT 3 ) receptor antagonism, and nausea induced by administration of an anti-neoplastic agent; It has been reported as a useful pharmaceutical compound for suppressing digestive symptoms such as vomiting (see Patent Document 1), and in particular, ramosetron hydrochloride is already on the market
- Ramosetron hydrochloride is also known to exert excellent pharmacological effects by oral administration of O.lmg once daily to adults, and is sold by Yamanouchi under the brand name Nazea OD Tablet O.lmg Have been.
- Serotonin receptor antagonists are also expected to be applied as irritable bowel syndrome (IBS) treatments because they stimulate serotonin (5-HT 3 ) receptors and increase acetylcholine release. ing.
- IBS irritable bowel syndrome
- serotonin (5-HT 3 ) receptors and increase acetylcholine release.
- serotonin receptor antagonists have been clinically confirmed to have therapeutic effects on irritable bowel syndrome patients, and the efficacy of ramosetron hydrochloride has not yet been reported.
- the present inventors have found that the therapeutically effective amount of ramosetron hydrochloride for irritable bowel syndrome is much lower than the dose O.lmg currently used as an inhibitor of gastrointestinal symptoms induced by administration of antineoplastic agents. I got the idea of a dose.
- the product Ramosetron Hydrochloride O.lmg tablet
- the product is packaged in a desiccant-containing package, so it is a pharmaceutically stable formulation and was not a problem as a marketed product.
- the stabilizing effect of the desiccant alone is considered to be insufficient for low-content preparations.
- Patent Document 1 European Patent No. 3 8 1 4 2 2 Disclosure of the Invention
- Ramosetron including ramosetron hydrochloride and pharmaceutically acceptable salts thereof, which are currently described, are slightly degraded by light irradiation, but are stable under temperature and humidity storage conditions.
- the present inventors have conducted studies on formulation that is most suitable for indications such as irritable bowel syndrome, which are expected to be effective at low doses, and found that ramosetron or a pharmaceutically acceptable salt thereof could be treated at high temperature and high humidity. I learned that when stored under the conditions, the quantitative value decreases and it is easily decomposed.
- the present inventors have conducted intensive studies to develop a formulation of ramosetron or a pharmaceutically acceptable salt thereof which is stable even at a low content.As a result, ascorbic acid showed a remarkable stabilizing effect on temperature and humidity. It was found that it played. The present inventors further studied the stabilizing effect of propyl gallate.Unexpectedly, the present inventors have found that the stabilizing effect of enol acids such as ascorbic acid and erythorbic acid, which exhibited an excellent stabilizing effect, was more surprising than that of enolic acid. We have found that propyl gallate has a much more pronounced stabilizing effect.
- Hydroxycarboxylic acids or their esters such as citric acid (hydrate), citric acid (anhydride), tartaric acid, and carboxymethylcellulose
- aromatic acids such as propyl gallic acid and aromatic aromatic acids such as propyl gallate and its esters
- the present inventors have further found that, in particular, when a colorant selected from the group consisting of yellow iron sesquioxide, red iron sesquioxide, and titanium oxide is added to ramoseton or a pharmaceutically acceptable salt thereof, However, they have also found that they have a very remarkable light stabilizing effect.
- a stable oral solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof characterized by containing one or more of the following:
- a stable oral solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof characterized in that:
- Ramosetron or a pharmaceutically acceptable salt thereof characterized by containing one or more selected from the group consisting of hydroxycarboxylic acid or its ester and a polymer substance having a hydroxyl group.
- hydroxycarboxylic acid or an ester thereof is one or more selected from the group consisting of tartaric acid, malic acid, and citric acid.
- composition according to the above 1, wherein the enolic acid is ascorbic acid or erythorbic acid
- composition according to the above 1, wherein the high molecular substance having a lipoxyl group is carboxymethylcellulose, or alginic acid.
- composition selected from the group consisting of aliphatic carboxylic acids or esters thereof, hydroxycarboxylic acids or esters thereof, acidic amino acids, enolic acid, aromatic lipoxyl compounds or esters thereof, and macromolecular substances having lipoxyl groups
- the pharmaceutical composition according to any one of the above 1 to 10, wherein the amount of the seed or two or more kinds is 0.01 to 90% by weight in the formulation.
- composition according to any one of the above items 1 to 13, further comprising a light stabilizer,
- the pharmaceutical composition according to the above 14, wherein the light stabilizer is one or more selected from the group consisting of yellow iron sesquioxide, red iron sesquioxide, and titanium oxide.
- Aliphatic carboxylic acids or esters thereof, hydroxycarboxylic acids or Ramosetron comprising one or more selected from the group consisting of: an ester, an acidic amino acid, an enolic acid, an aromatic lipoxyl compound or an ester thereof, and a polymer having a lipoxyl group.
- a method for stabilizing an oral solid pharmaceutical composition of a pharmaceutically acceptable salt thereof
- Aliphatic carboxylic acid or an ester thereof is maleic acid, malonic acid, succinic acid, and one or more selected from the group consisting of fumaric acid.
- hydroxycarboxylic acid or an ester thereof is one or more selected from the group consisting of tartaric acid, malic acid, and citric acid,
- antioxidants are classified into three types according to their mechanism of action. See “Development of Pharmaceuticals, Vol. 12, Pharmaceutical Materials ⁇ p.310, published on October 28, 1990”. Is a substance that oxidizes and consumes oxygen instead of a chemical that is vulnerable to oxidation (eg, a water-soluble reducing agent such as ascorbic acid), and 2 reacts as a free radical receptor to block the chain reaction Substances that are thought to be possible (eg, fat-soluble antioxidants such as propyl gallate), and (3) substances that have no antioxidant effect by themselves, but that when combined with an antioxidant enhance the antioxidant effect ( For example, synergist (a synergist) which is a fat-soluble antioxidant such as cunic acid is mentioned.
- the present invention discloses that cunic acid, which has almost no antioxidant activity, is replaced by other antioxidant agents. Since the drug provided a more stable ramosetron formulation than the drug, it is presumed that the suppression of degradation under temperature and humidity storage conditions was not based on mere oxidative degradation suppression.
- the present invention relates to a pharmaceutical composition that is stable against racemization and contains a water-soluble acidic substance, in comparison with a 5-HT receptor antagonist silanesetron, which is an optically active substance and racemizes in a pharmaceutical preparation.
- the invention has been disclosed (JP-A-11-92369). However, the technical issues are different from those for suppressing racemization. Furthermore, the present inventors conducted a 12-week clinical test on patients with diarrhea-sensitive irritable bowel syndrome using the above-mentioned stabilized preparation of ramosetron hydrochloride having a low content, and confirmed remarkable efficacy. Completed the invention.
- composition for the treatment of irritable bowel syndrome with diarrhea containing 0.002-0.02 mg of ramosetron hydrochloride or an equimolar amount of ramosetron or other pharmaceutically acceptable salt as an active ingredient per day Object or
- composition for improving diarrhea symptom of irritable gland syndrome comprising as an active ingredient 0.001 to 0.02 mg of ramosetron hydrochloride or an equimolar amount of ramosetron or other pharmaceutically acceptable salt as a daily dose Things, about.
- Treatment of irritable bowel syndrome with diarrhea including administering to patients a daily dose of 0.002-0.02 mg of ramosetron hydrochloride or an equimolar amount of ramosetron or other pharmaceutically acceptable salt Method or
- Test Example 2 The clinical test results shown in Test Example 2 below indicate that the dose of ramoseton hydrochloride is 0.005 mg and O.Olmg once daily. However, the therapeutic effect was as significant as O.Olmg by the administration of 0.005 mg, and the efficacy can be expected even with about half this amount.
- the subjects of Test Example 2 were Japanese adult patients and children. It is suggested that the optimal dose may be even smaller, and it is often the case that the optimal dose for Europeans and Americans is twice that for Japanese. Therefore, the particularly preferred dose of ramosetron hydrochloride is in the range of 0.002 to 0.02 mg daily, but depending on the age and ethnicity of the patient, the daily dose of irritable bowel syndrome can be in the range of 0.001 to 0.05 mg. Alternatively, it is thought that diarrhea symptoms of the irritable bowel syndrome group can be improved.
- the oral pharmaceutical composition of the present invention will be described below.
- Ramosetron used in the present invention is a pharmaceutical compound having the above-mentioned chemical name and described in JP-B-6-25153, Example 44.
- the pharmaceutically acceptable salt thereof is specifically hydrochloric acid.
- Mineral salts with sulfuric acid, phosphoric acid, hydrobromic acid, etc. salts with organic acids such as acetic acid, oxalic acid, succinic acid, citric acid, maleic acid, malic acid, fumaric acid, tartaric acid, methanesulfonic acid, etc.
- salts with acidic amino acids such as glutamic acid and aspartic acid.
- commercially available ramosetron hydrochloride is preferable.
- Ramosetron or a pharmaceutically acceptable salt thereof can be easily obtained by the production method described in the above publication.
- the amount of ramosetron or a pharmaceutically acceptable salt thereof is not particularly limited as long as it is an effective amount, especially if it is found to be unstable to temperature and humidity in a low-dose formulation. However, it is presumed that this is an inherent problem even with high-content pharmaceuticals, so a similar stabilizing effect is expected. Therefore, the present invention is not limited to the effective amount for the indication of irritable bowel syndrome, but also includes the effective amount of a conventional commercially available product. Specifically, the amount of ramosetron or a pharmaceutically acceptable salt thereof is 0.0001 to 0.5% by weight in the formulation, more preferably 0.0001 to 0.25% by weight in the formulation, and even more preferably 0.0005 to 0.25% by weight in the formulation. ⁇ 0.05% by weight. In addition, when expressed in the unit dose of ramosetron or a pharmaceutically acceptable salt thereof, it is specifically 0.1 to 500 g, more preferably 0 :! to 250 g, More preferably:!
- the compound for stabilizing ramosetron used in the present invention is a specific compound having a carbonyl group as described above, and is ramosetron or a compound thereof. It stabilizes pharmaceutically acceptable salts.
- Specific compounds having a carbonyl group include aliphatic carboxylic acids (specifically, saturated or unsaturated, linear or branched aliphatic mono-, di- or tri-carboxylic acids.
- an aliphatic carboxylic acid having 3 to 36 carbon atoms or an ester thereof hydroxycarboxylic acid (specifically, a saturated or unsaturated, linear or branched aliphatic hydroxy mono-, di- or Tricarboxylic acids, especially hydroxycarboxylic acids having 3 to 36 carbon atoms) or their esters, acidic amino acids, enolic acid, aromatic ropoxyl compounds (specifically, alkyl groups having 1 to 4 carbon atoms ⁇ hydroxy groups) May be substituted with an aromatic mono-, di- or tricarboxylic acid, especially an aromatic carboxylic acid having 7 to 20 carbon atoms) or an ester thereof, or a lipoxyl group
- Polymer substances may be mentioned which has, these compounds can be appropriately used in combination of two or more.
- a polymer having a carboxyl group, an aromatic carboxylic acid compound or an ester thereof, and enoic acid are preferable.
- An acid or an ester thereof, a polymer substance having a lipoxyl group, and an aromatic lipoxyl compound or an ester thereof are preferable, and most preferably a hydroxycarboxylic acid or an ester thereof, or a polymer substance having a lipoxyl group is more preferable. Good.
- Preferred aliphatic carboxylic acids are maleic acid, malonic acid, succinic acid, and fumaric acid.
- the hydroxycarboxylic acid is preferably tartaric acid, malic acid or citric acid, more preferably tartaric acid or citric acid.
- As the acidic amino acid preferred is aspartic acid glutamate.
- Preferred aromatic propyloxyl compounds are fumaric acid and propyl gallate, more preferably propyl gallate.
- Carboxymethylcellulose and alginic acid are preferred as the high molecular substance having a hydroxyl group, and still more preferred are carboxymethylcellulose.
- enolic acid preferred are ascorbic acid and erythorbic acid, and more preferred is ascorbic acid. W
- hydrates and anhydrides having no water of crystallization such as hydrated hydrate or hydrated anhydride
- hydrates, anhydrides, and mixtures thereof The degree of polymerization and the molecular weight of the high molecular substance are not particularly limited. However, it is preferable that the weight average molecular weight of carboxymethyl cellulose is about 110,000, and that of alginic acid is about 200,000.
- the compounding amount of the compound that stabilizes ramosetron or a pharmaceutically acceptable salt thereof is not limited as long as the amount stabilizes ramosetron or a pharmaceutically acceptable salt thereof (preferably ramosetron hydrochloride). .
- it is 0.01 to 90% by weight, preferably 0.01 to 50% by weight, and more preferably 0.1 to 10% by weight in view of productivity.
- Such a pharmaceutical additive is not particularly limited as long as it is a pharmaceutically acceptable additive.
- excipients include lactose, crystalline cell mouth, microcrystalline cellulose, D-sorbitol, D-mannitol and the like.
- binder include hydroxypropylmethylcellulose, hydroxypropylcellulose, povidone, polyvinyl alcohol, methylcellulose, and gum arabic.
- Disintegrators include, for example, corn starch, potato starch, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone and the like.
- acidulant for example, citric acid, tartaric acid, malic acid and the like can be mentioned.
- foaming agent include baking soda.
- artificial sweeteners include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin and the like.
- flavors include lemon, lemon lime, orange, and menthol.
- Lubricants include, for example, magnesium stearate, calcium stearate, sucrose fatty acid ester, polyethylene glycol, Luk, stearic acid and the like.
- the coloring agent for example, yellow iron sesquioxide, red iron sesquioxide, titanium oxide, edible yellow 4, 5, edible red 3, 102, edible blue 3, etc. can be used.
- yellow iron sesquioxide, red iron sesquioxide and titanium oxide are blended, a remarkable light stabilizing effect is exhibited, and these colorants also act as light stabilizers.
- an appropriate amount can be appropriately added alone or in combination of two or more.
- the pharmaceutical composition of the present invention can be produced by a method known per se, for example, into powders, tablets, film-coated tablets, orally disintegrating tablets and the like.
- Many orally disintegrating tablet technologies have been developed in recent years, but are not particularly limited.
- ramosetron or a pharmaceutically acceptable salt thereof may be partially or wholly added during granulation.
- Wet granulation as a binding solution containing a coloring agent or powder containing a coloring agent can be produced by wet granulation with a binding solution containing ramosetron or a pharmaceutically acceptable salt thereof.
- the amount of the colorant to be added is appropriately determined depending on the type of the colorant and the method of addition. For example, in the case of a film coat, it is usually 0.01 to 10% by weight, preferably 0.05 to 2% by weight, based on the whole composition.
- wet granulation is performed as a binding solution containing ramosetron or a pharmaceutically acceptable salt thereof and part or all of the dye, or powder containing the dye is ramosetron or a pharmaceutically acceptable salt thereof.
- a binding solution containing a salt it is usually 0.1 to 20% by weight, preferably 0.2 to 10% by weight, and more preferably the productivity in consideration of the whole composition. And 0.2-5% by weight.
- ramosetron or its pharmaceutically acceptable salt a step of dissolving or suspending an organic acid and a coloring agent as needed in purified water, an excipient, and an organic acid and a coloring agent as necessary
- the aqueous solution or suspension is added to the powder in a wet granulator such as a fluidized bed granulator. Spraying and drying.
- a pharmaceutically acceptable pharmaceutical additive may be uniformly dispersed and added to the aqueous solution or suspension and / or the powder to be fluidized.
- the aqueous solutions and suspensions are usually used at a concentration as a binder performed in wet granulation.
- the oral solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof of the present invention can be stabilized by the method described in the description of the invention relating to the pharmaceutical composition.
- the mixed powder was tableted at 120 mg per tablet using a rotary tableting machine to give tablets having an initial hardness of about lkp. This was stored at 25 ° C and a relative humidity of 75% for 18 hours, and then stored at 30 ° C and a relative humidity of 40% for 4 hours to obtain the preparation of the present invention. A comparative tablet was obtained.
- the mixed powder was tableted at 120 mg / tablet using a rotary tableting machine to give tablets having an initial hardness of about lkp. This was stored at 25 ° C and a relative humidity of 75% for 18 hours, and then stored at 30: and a relative humidity of 40% for 4 hours to obtain an orally disintegrating tablet of the preparation of the present invention.
- An orally disintegrating tablet of the present preparation was obtained by the same production method as in Example 2 except that the amount of citrate anhydride was changed to 0.2 part.
- An orally disintegrating tablet of the present invention was obtained in the same production method as in Example 2, except that the amount of citrate anhydride was changed to 0.5 part.
- the mixed powder was tableted at 120 mg per tablet using a rotary tableting machine to give tablets having an initial hardness of about lkp. This was stored at 25 ° C and a relative humidity of 75% for 18 hours, and then stored at 30 ° C and a relative humidity of 40% for 4 hours to obtain an orally disintegrating tablet of the preparation of the present invention.
- a tablet was prepared in the same manner as in Example 5 except that the amount of ascorbic acid was changed to 0.5 part, to give an orally disintegrating tablet of the preparation of the present invention.
- the granulated product was dried at an intake air temperature of 40 ° C for 5 minutes, and then 1 part of magnesium stearate was mixed. That The mixed powder was tableted at 120 mg per tablet using a single-tally tableting machine to give tablets having an initial hardness of about lkp. This was stored at 25 ° C and a relative humidity of 75% for 18 hours, and then stored at 30 ° C and a relative humidity of 40% for 4 hours to obtain an orally disintegrating tablet of the preparation of the present invention.
- Hydroxypropylcellulose 3 parts, citric acid hydrate 0.5 parts, and ramosetron hydrochloride 0.01 parts were stirred and dissolved in 27 parts of water using a magnetic stirrer to prepare a spray solution (hydroxypropylcellulose concentration 10% by weight). .
- a spray solution hydroxypropylcellulose concentration 10% by weight.
- 86 parts of Avicel and 10 parts of low-substituted hydroxypropylcellulose are charged into a fluidized bed granulator (product name: GPCG-5, manufactured by Palex Corporation), and the spray liquid is sprayed at a spray rate of 100 g / min.
- a fluidized bed granulator product name: GPCG-5, manufactured by Palex Corporation
- the spray liquid is sprayed at a spray rate of 100 g / min.
- the granulated product was dried at an intake air temperature of 40 ° C. for 5 minutes, and then 0.5 part of magnesium stearate was mixed.
- the mixed powder was tableted at 100
- the preparation of the present invention was stored under various storage conditions (25 ° C 75% RH bottle open, 40t 75% RH bottle open, 25 60% RH bottle sealed, 40 ° C 75% RH bottle sealed, or lOOOLux-white fluorescent lamp irradiation After storage for a certain period of time, the quantitative value of the preserved product under various conditions relative to the quantitative value of the preserved product at 5 ° C was calculated to evaluate the stabilizing effect of the present formulation. The quantification was performed by a liquid chromatography method. ⁇ Results and discussion>
- the ramosetron hydrochloride 1 g tablet containing no specific compound having a carbonyl compound in Comparative Example 2 contained a smaller amount of ramosetron hydrochloride than Comparative Example 1, and thus a significantly lower quantitative value was observed.
- the quantitative values of the tablets containing citrate anhydride of Examples 2, 3, and 4, which also contain a small amount of ramosetron hydrochloride showed almost no change compared to the tablets stored at 5 ° C.
- the tablets containing ascorbic acid of Examples 5 and 6, compared with Comparative Example 2 the effect of improving the stability of ramosetron hydrochloride to temperature and humidity was observed.
- Ramosetron hydrochloride tablets containing propyl gallate were evaluated for stability of ramosetron hydrochloride in the preparation of the present invention under temperature and humidity conditions. Table 6 shows the results.
- the ramosetron hydrochloride containing propyl gallate of Example 10 g tablets showed a stabilizing effect as compared with the ramosetron hydrochloride lg tablet containing no specific compound having a lipoyl group of Comparative Example 2 in the quantitative value. .
- IBS diarrhea irritable bowel syndrome
- Investigational drug and administration method placebo and ramosetron hydrochloride 5 g and lO g were orally administered once daily for 12 weeks
- Study period 1 week observation period, 12 weeks treatment period
- the subjects compare all the symptoms of IBS every week and compare the overall improvement effect of the study drug on the IBS symptoms with the observation period And evaluated and completed in the patient diary.
- the scores for the overall improvement effect on IBS symptoms were as follows.
- Monthly monthly responder rates were calculated for each group of placebo, ramosetron hydrochloride 5 g, and, with subjects who scored 0 or 1 for 2 weeks or more out of 4 weeks as the monthly responders.
- the subjects After the transition to the treatment period, starting on the first day of taking the investigational drug, the subjects evaluated the effects of the investigational drug on improving abdominal pain and abdominal discomfort every week, comparing with the state during the observation period, and filled out the patient diary.
- the evaluation scores for the effect of improving abdominal pain and abdominal discomfort were as follows. ,
- subjects recorded their daily stool shape (properties) in the patient diary using the score (type) of the Bristol Stool Shape Scale (Appendix 3). If the bowel movements were repeated several times a day, or if the bowel movements had different stool shapes (characteristics) in a single bowel movement, the subject's most representative stool of the day (felt most annoying) Only one shape (property) was entered.
- the final monthly responder rate for the overall improvement of IBS symptoms was 26.9% in the placebo group.
- ramosetron hydrochloride and 10 g The responder rates were 42.6% and 43.0%, respectively, which exceeded the placebo responder rate by more than 15%.
- the p-values for the 5 ⁇ g and 10 / 2g groups for the placebo group were 0.0273 and 0.0264, respectively.
- the rate of the last month's response to abdominal pain, abdominal discomfort and the effect of improving bowel movements were more than 10% higher in the ramosetron hydrochloride 5 g and 10 ⁇ g groups than in the placebo group.
- the oral solid pharmaceutical composition of the present invention can provide a stable preparation under temperature and humidity conditions, especially even with a low content of ramosetron or a pharmaceutically acceptable salt thereof.
- an excellent therapeutic agent for diarrhea-type irritable bowel syndrome effective in clinical practice or an agent for improving diarrheal symptoms of irritable bowel syndrome can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04706797A EP1588707B1 (en) | 2003-01-31 | 2004-01-30 | Stable solid medicinal composition for oral administration of ramosetron |
DE602004019049T DE602004019049D1 (de) | 2003-01-31 | 2004-01-30 | Stabile feste medizinische zusammensetzung für die orale verabreichung von ramosetron |
NZ537448A NZ537448A (en) | 2003-01-31 | 2004-01-30 | Stable solid medicinal composition for oral administration |
AU2004208617A AU2004208617B2 (en) | 2003-01-31 | 2004-01-30 | Stable solid medicinal composition for oral administration |
BR0405221-8A BRPI0405221A (pt) | 2003-01-31 | 2004-01-30 | Composição medicinal estável sólida para administração oral |
MXPA04012462A MXPA04012462A (es) | 2003-01-31 | 2004-01-30 | Composicion medicinal solida estable para la administracion oral. |
DK04706797T DK1588707T3 (da) | 2003-01-31 | 2004-01-30 | Stabilt fast medicinsk præparat til oral administration af ramosetron |
JP2004564051A JP3689104B2 (ja) | 2003-01-31 | 2004-01-30 | 安定な経口用固形医薬組成物 |
CA002488422A CA2488422C (en) | 2003-01-31 | 2004-01-30 | Stable solid medicinal ramosetron composition for oral administration |
JP2004141975A JP3763360B2 (ja) | 2004-01-30 | 2004-05-12 | 下痢型過敏性腸症候群治療剤 |
PCT/JP2004/006657 WO2005073220A1 (ja) | 2004-01-30 | 2004-05-12 | 下痢型過敏性腸症候群治療剤 |
US10/928,464 US7794748B2 (en) | 2003-01-31 | 2004-08-27 | Stable oral solid drug composition |
IL165371A IL165371A (en) | 2003-01-31 | 2004-11-24 | Stable solid medicinal composition comprising remosetron and salts thereof for oral administration |
NO20045153A NO20045153L (no) | 2003-01-31 | 2004-11-25 | Stabilt, fast medisinpreparat for oral administrasjon |
KR1020057016208A KR100746444B1 (ko) | 2004-01-30 | 2005-01-27 | 설사-우세형 과민성 대장 증후군의 치료제 |
PL380448A PL380448A1 (pl) | 2004-01-30 | 2005-01-27 | Środek do leczenia dominującego zespołu drażliwego jelita grubego typu biegunkowego |
MXPA05009025A MXPA05009025A (es) | 2004-01-30 | 2005-01-27 | Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante. |
BRPI0503488-4A BRPI0503488A (pt) | 2004-01-30 | 2005-01-27 | agente de tratamento para sìndrome de intestino irritável com diarréia predominante |
PCT/JP2005/001549 WO2005072730A1 (ja) | 2004-01-30 | 2005-01-27 | 下痢型過敏性腸症候群治療剤 |
NZ541656A NZ541656A (en) | 2004-01-30 | 2005-01-27 | The use of ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome |
AU2005209112A AU2005209112B2 (en) | 2004-01-30 | 2005-01-27 | Therapeutic agent for diarrhea-type irritable bowel syndrome |
CA002516433A CA2516433C (en) | 2004-01-30 | 2005-01-27 | Ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome |
CNB2005800000636A CN100372533C (zh) | 2004-01-30 | 2005-01-27 | 腹泻为主大肠激惹综合征的治疗制剂 |
RU2005127333/15A RU2314808C2 (ru) | 2004-01-30 | 2005-01-27 | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи |
US11/047,142 US7358270B2 (en) | 2004-01-30 | 2005-01-28 | Treating agent for irritable bowel syndrome |
EP05001928A EP1559446B1 (en) | 2004-01-30 | 2005-01-31 | Treating agent for diarrhea-predominant irritable bowel syndrome |
AT05001928T ATE516061T1 (de) | 2004-01-30 | 2005-01-31 | Medikament zur behandlung des reizdarmsyndroms mit diarrhö |
ES05001928T ES2367896T3 (es) | 2004-01-30 | 2005-01-31 | Agente para el tratamiento del sindrome del colon irritable con predominio de diarrea. |
ZA200506503A ZA200506503B (en) | 2003-01-31 | 2005-08-15 | Therapeutic agent for diarrhea-type irritable bowel syndrome |
NO20054002A NO20054002L (no) | 2004-01-30 | 2005-08-29 | Behandlingsmiddel for diar±-predominant irritabel tarmsyndrom |
HK06104829A HK1084582A1 (en) | 2003-01-31 | 2006-04-24 | Stable solid medicinal composition for oral administration |
US11/583,234 US7683090B2 (en) | 2004-01-30 | 2006-10-18 | Treating agent for irritable bowel syndrome |
HK06111414A HK1090561A1 (en) | 2004-01-30 | 2006-10-18 | Therapeutic agent for diarrhea-type irritable bowel syndrome |
RU2007119067/15A RU2351327C2 (ru) | 2004-01-30 | 2007-05-22 | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003023500 | 2003-01-31 | ||
JP2003-023500 | 2003-01-31 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006657 Continuation-In-Part WO2005073220A1 (ja) | 2004-01-30 | 2004-05-12 | 下痢型過敏性腸症候群治療剤 |
US10/928,464 Continuation US7794748B2 (en) | 2003-01-31 | 2004-08-27 | Stable oral solid drug composition |
US11/047,142 Continuation-In-Part US7358270B2 (en) | 2004-01-30 | 2005-01-28 | Treating agent for irritable bowel syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004066998A1 true WO2004066998A1 (ja) | 2004-08-12 |
Family
ID=32820728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000896 WO2004066998A1 (ja) | 2003-01-31 | 2004-01-30 | 安定な経口用固形医薬組成物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7794748B2 (ja) |
EP (1) | EP1588707B1 (ja) |
JP (1) | JP3689104B2 (ja) |
KR (1) | KR100633836B1 (ja) |
CN (1) | CN100379416C (ja) |
AT (1) | ATE420638T1 (ja) |
AU (1) | AU2004208617B2 (ja) |
BR (1) | BRPI0405221A (ja) |
CA (1) | CA2488422C (ja) |
DE (1) | DE602004019049D1 (ja) |
DK (1) | DK1588707T3 (ja) |
ES (1) | ES2319292T3 (ja) |
HK (1) | HK1084582A1 (ja) |
IL (1) | IL165371A (ja) |
MX (1) | MXPA04012462A (ja) |
NO (1) | NO20045153L (ja) |
NZ (1) | NZ537448A (ja) |
PL (1) | PL375181A1 (ja) |
PT (1) | PT1588707E (ja) |
RU (1) | RU2284819C2 (ja) |
WO (1) | WO2004066998A1 (ja) |
ZA (2) | ZA200409537B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008032726A1 (fr) | 2006-09-15 | 2008-03-20 | Astellas Pharma Inc. | Composition pharmaceutique solide pour administration orale comprenant du ramosétron optiquement stable |
US10307418B2 (en) | 2010-12-16 | 2019-06-04 | Platform Brightworks Two, Ltd. | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
US10548890B2 (en) | 2011-04-28 | 2020-02-04 | Platform Brightworks Two, Ltd. | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
US7358270B2 (en) * | 2004-01-30 | 2008-04-15 | Astellas Pharma Inc. | Treating agent for irritable bowel syndrome |
GEP20125420B (en) * | 2006-08-10 | 2012-03-26 | Takeda Pharmaceutical | Solid pharmaceutical composition comprising benzimidazole compound |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2555828B1 (en) * | 2010-04-09 | 2017-07-19 | Unilever PLC, a company registered in England and Wales under company no. 41424 | Oral care compositions |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP3513788B1 (en) * | 2015-03-19 | 2020-07-29 | Daiichi Sankyo Company, Limited | Solid preparation containing colorant |
CA2980096C (en) | 2015-03-19 | 2019-12-17 | Daiichi Sankyo Company, Limited | Solid preparations of [(1r,5s,6s)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate stabilized by containing a specific antioxidant, and methodsfor preparing the same |
CN106937946B (zh) * | 2016-01-05 | 2020-05-12 | 山东诚创医药技术开发有限公司 | 盐酸雷莫司琼泡腾片及其制备方法 |
CN107224430A (zh) * | 2016-03-25 | 2017-10-03 | 江苏奥赛康药业股份有限公司 | 一种含盐酸雷莫司琼的药物组合物 |
KR102349971B1 (ko) * | 2016-04-27 | 2022-01-12 | 주식회사 엘지생활건강 | 폴리다틴 또는 이의 약학적으로 허용 가능한 염의 광 안정화용 조성물 |
ES2943883T3 (es) | 2018-07-30 | 2023-06-16 | Daiichi Sankyo Co Ltd | Formulación de fármaco sólido que contiene estabilizador |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4067974A (en) * | 1976-01-21 | 1978-01-10 | The Purdue Frederick Company | Stabilized solid form choline salicylate compositions |
EP0274845A1 (en) * | 1986-12-10 | 1988-07-20 | The Boots Company PLC | Stable solid pharmaceutical composition containing ibuprofen and codeine |
JPH0565226A (ja) * | 1991-09-10 | 1993-03-19 | Taisho Pharmaceut Co Ltd | アミノアルキルピリジルオキシ誘導体の安定化組成物 |
WO1999017755A2 (en) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
EP1205190A1 (en) * | 1999-08-04 | 2002-05-15 | Yamanouchi Pharmaceutical Co. Ltd. | Stable medicinal compositions for oral use |
US20020150624A1 (en) * | 2000-07-17 | 2002-10-17 | Shunsuke Watanabe | Pharmaceutical composition for oral use with improved absorption |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB759081A (en) * | 1954-04-15 | 1956-10-10 | John Holroyd And Company Ltd | Improvements relating to machines for the production of coated tablets and the like |
US5223508A (en) * | 1988-12-27 | 1993-06-29 | Kirin Beer Kabushiki Kaisha | Pyridyl carboximidamide compounds useful in treating blood pressure |
US5344927A (en) * | 1989-02-02 | 1994-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Tetrahydrobenzimidazole derivatives and pharmaceutical compositions containing same |
US5107887A (en) | 1990-12-03 | 1992-04-28 | The Aro Corporation | High pressure fluid regulator |
TWI285644B (en) | 1997-07-11 | 2007-08-21 | Toray Industries | A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant |
DK1038525T3 (da) | 1997-10-20 | 2004-08-02 | Dainippon Pharmaceutical Co | Stabiliseret farmaceutisk præparat af tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3'-pyrrolidin |
KR20020019967A (ko) | 1999-08-09 | 2002-03-13 | 메텔리, 라파엘라 | 에스트라무스틴 포스페이트 및 알부민의 비경구용 제형 |
DE19941997A1 (de) * | 1999-09-02 | 2001-03-08 | Gunther Meinhardt Voss | Verfahren und Vorrichtung zur Herstellung einer Tablette o. dgl. |
US6566369B2 (en) * | 2000-07-26 | 2003-05-20 | Solvay Pharmaceuticals Gmbh | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
KR100530546B1 (ko) * | 2001-07-27 | 2005-11-23 | 아스텔라스세이야쿠 가부시키가이샤 | 구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법 |
GB0119012D0 (en) * | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
US20030143548A1 (en) | 2002-01-28 | 2003-07-31 | Camilleri Michael L. | Predicting patient responsiveness to serotonergic therapy |
ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
US7358270B2 (en) | 2004-01-30 | 2008-04-15 | Astellas Pharma Inc. | Treating agent for irritable bowel syndrome |
-
2004
- 2004-01-01 ZA ZA200409537A patent/ZA200409537B/en unknown
- 2004-01-30 PT PT04706797T patent/PT1588707E/pt unknown
- 2004-01-30 ES ES04706797T patent/ES2319292T3/es not_active Expired - Lifetime
- 2004-01-30 CA CA002488422A patent/CA2488422C/en not_active Expired - Fee Related
- 2004-01-30 AT AT04706797T patent/ATE420638T1/de active
- 2004-01-30 RU RU2004136181/15A patent/RU2284819C2/ru not_active IP Right Cessation
- 2004-01-30 MX MXPA04012462A patent/MXPA04012462A/es active IP Right Grant
- 2004-01-30 CN CNB2004800003517A patent/CN100379416C/zh not_active Expired - Fee Related
- 2004-01-30 AU AU2004208617A patent/AU2004208617B2/en not_active Ceased
- 2004-01-30 DK DK04706797T patent/DK1588707T3/da active
- 2004-01-30 EP EP04706797A patent/EP1588707B1/en not_active Expired - Lifetime
- 2004-01-30 DE DE602004019049T patent/DE602004019049D1/de not_active Expired - Lifetime
- 2004-01-30 PL PL04375181A patent/PL375181A1/xx unknown
- 2004-01-30 JP JP2004564051A patent/JP3689104B2/ja not_active Expired - Lifetime
- 2004-01-30 BR BR0405221-8A patent/BRPI0405221A/pt not_active IP Right Cessation
- 2004-01-30 WO PCT/JP2004/000896 patent/WO2004066998A1/ja active Application Filing
- 2004-01-30 NZ NZ537448A patent/NZ537448A/en not_active IP Right Cessation
- 2004-01-30 KR KR1020047020096A patent/KR100633836B1/ko active Protection Beyond IP Right Term
- 2004-08-27 US US10/928,464 patent/US7794748B2/en not_active Expired - Fee Related
- 2004-11-24 IL IL165371A patent/IL165371A/en not_active IP Right Cessation
- 2004-11-25 NO NO20045153A patent/NO20045153L/no not_active Application Discontinuation
-
2005
- 2005-08-15 ZA ZA200506503A patent/ZA200506503B/xx unknown
-
2006
- 2006-04-24 HK HK06104829A patent/HK1084582A1/xx not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4067974A (en) * | 1976-01-21 | 1978-01-10 | The Purdue Frederick Company | Stabilized solid form choline salicylate compositions |
EP0274845A1 (en) * | 1986-12-10 | 1988-07-20 | The Boots Company PLC | Stable solid pharmaceutical composition containing ibuprofen and codeine |
JPH0565226A (ja) * | 1991-09-10 | 1993-03-19 | Taisho Pharmaceut Co Ltd | アミノアルキルピリジルオキシ誘導体の安定化組成物 |
WO1999017755A2 (en) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
EP1205190A1 (en) * | 1999-08-04 | 2002-05-15 | Yamanouchi Pharmaceutical Co. Ltd. | Stable medicinal compositions for oral use |
US20020150624A1 (en) * | 2000-07-17 | 2002-10-17 | Shunsuke Watanabe | Pharmaceutical composition for oral use with improved absorption |
Non-Patent Citations (4)
Title |
---|
KISHIBAYASHI NOBUYUKI ET AL.: "5-HT3 receptor antagonists.,3 quinoine derivatives which may be effective in the therapy of irritable bowel syndrome", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 22, 1993, pages 3286 - 3292, XP002158321 * |
KUWABARA TOSHIYUKI ET AL.: "Regulation of 60kDa heat shock protein expression by systemic stress and 5-hydroxytryptamine in rat colonic mucosa", JOURNAL OF GASTROENTEROLOGY, vol. 29, no. 26, 1994, pages 721 - 726, XP002904482 * |
MASAKI KATSUHIRO ET AL.: "5-HT3 juyotai kikkogata seitozai 'nazea OD jyo 0.1mg' no butsuri kagakuteki seishitsu oyobi anteisei", ANTIBIOTICS & CHEMOTHERAPY, vol. 14, no. 3, 1998, pages 2004 - 2008, XP002904481 * |
YAKUJI NIPPO LTD, 14 January 1994 (1994-01-14), JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL, IYAKUHIN TENKABUTSU JITEN, pages 2 - 3, 18, 39, 65, 113, 117, XP002904480 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008032726A1 (fr) | 2006-09-15 | 2008-03-20 | Astellas Pharma Inc. | Composition pharmaceutique solide pour administration orale comprenant du ramosétron optiquement stable |
JP5365777B2 (ja) * | 2006-09-15 | 2013-12-11 | アステラス製薬株式会社 | 光に対して安定なラモセトロンの固形医薬組成物 |
US10307418B2 (en) | 2010-12-16 | 2019-06-04 | Platform Brightworks Two, Ltd. | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
US10548890B2 (en) | 2011-04-28 | 2020-02-04 | Platform Brightworks Two, Ltd. | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
US11045466B2 (en) | 2011-04-28 | 2021-06-29 | Platform Brightworks Two, Ltd. | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004066998A1 (ja) | 2006-05-18 |
IL165371A (en) | 2009-08-03 |
NO20045153L (no) | 2005-02-04 |
EP1588707A4 (en) | 2006-03-15 |
ATE420638T1 (de) | 2009-01-15 |
JP3689104B2 (ja) | 2005-08-31 |
ZA200409537B (en) | 2006-10-25 |
KR100633836B1 (ko) | 2006-10-13 |
AU2004208617A2 (en) | 2004-08-12 |
HK1084582A1 (en) | 2006-08-04 |
CN100379416C (zh) | 2008-04-09 |
KR20050044772A (ko) | 2005-05-12 |
ZA200506503B (en) | 2006-12-27 |
MXPA04012462A (es) | 2005-02-24 |
DK1588707T3 (da) | 2009-03-09 |
ES2319292T3 (es) | 2009-05-06 |
PL375181A1 (en) | 2005-11-28 |
BRPI0405221A (pt) | 2005-03-15 |
EP1588707A1 (en) | 2005-10-26 |
EP1588707B1 (en) | 2009-01-14 |
CA2488422A1 (en) | 2004-08-12 |
CN1723021A (zh) | 2006-01-18 |
AU2004208617B2 (en) | 2007-09-13 |
RU2004136181A (ru) | 2005-08-10 |
PT1588707E (pt) | 2009-03-27 |
US20050026981A1 (en) | 2005-02-03 |
RU2284819C2 (ru) | 2006-10-10 |
IL165371A0 (en) | 2006-01-15 |
AU2004208617A1 (en) | 2004-08-12 |
NZ537448A (en) | 2008-06-30 |
US7794748B2 (en) | 2010-09-14 |
DE602004019049D1 (de) | 2009-03-05 |
CA2488422C (en) | 2008-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004066998A1 (ja) | 安定な経口用固形医薬組成物 | |
TWI388316B (zh) | 抑制胃酸分泌之組合物及方法 | |
JP6173521B2 (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
US20070105894A1 (en) | Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor | |
CN100341506C (zh) | 含有阿斯匹林的药用组合物 | |
KR20090034372A (ko) | 옥시코돈을 포함하는 과립 및 경구 붕해 정제 | |
JP4816828B2 (ja) | ソリフェナシン非晶質体を含有した固形医薬組成物 | |
JP4632204B2 (ja) | 下痢型過敏性腸症候群治療剤 | |
KR20190059868A (ko) | 바레니클린 살리실레이트를 함유하는 서방성 제제 및 이의 제조 방법 | |
JP2014240435A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
KR100746444B1 (ko) | 설사-우세형 과민성 대장 증후군의 치료제 | |
WO2022184981A1 (en) | Stable pharmaceutical compositions of metformin | |
JPWO2003075919A1 (ja) | 塩酸ピルジカイニド含有錠剤(乾式) | |
TW200529817A (en) | Stabilized pharmaceutical compositions | |
WO2005072730A1 (ja) | 下痢型過敏性腸症候群治療剤 | |
JP2013006843A (ja) | 胃酸分泌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2004564051 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10928464 Country of ref document: US |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/09537 Country of ref document: ZA Ref document number: 200409537 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501943 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3775/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2488422 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004208617 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004136181 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 375181 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/012462 Country of ref document: MX Ref document number: 1020047020096 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048003517 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537448 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2004208617 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047020096 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004706797 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004706797 Country of ref document: EP |